Big Data Genetics Genomics Protein 
Drug Discovery World
JULY 11, 2023
Drug discovery and development timelines can span 10-15 years or more from initial discovery to market approval and typically require the analysis of massive amounts of data. One system that has been especially useful in generating relevant and accurate biological data is the patient- derived xenograft (PDX) model for cancer studies.
pharmaphorum
SEPTEMBER 16, 2022
A mere six months ago Verily launched the study with Sosei Heptares – a global leader in GPCR structure-based drug design – with an aim to “prioritise protein targets for therapeutic targeting in immune-mediated disease”. Verily’s Immune Profiler can, Kim asserted, “generate more than 8 million immune measures across 24 immune cell subsets”.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
JULY 17, 2024
A global collaboration led by scientists at the University of Oxford has discovered that genetic variants in a specific gene cause a rare neurodevelopmental disorder (NDD). This discovery was initially made using data from the 100,000 Genomes Project, a study led by Genomics England and NHS England.
Drug Discovery World
FEBRUARY 6, 2024
Sanofi has stated that it intends to become the first pharma company “powered by AI at scale”, and as part of this ambition, agreed a collaboration with BioMap to co-develop advanced AI models and protein Large Language Models that that it hopes will enable biologics design and multiparametric optimisation 2.
Drug Discovery World
FEBRUARY 6, 2023
Johannes Goll, Global Head of Emmes’ Biomedical Data Science and Bioinformatics department, explains how big data analytics can deliver improved therapies and bring clinical research one step close to realising the potential of personalised care.
pharmaphorum
SEPTEMBER 18, 2020
The same year, AZ also entered into its third collaboration agreement with Astex Therapeutics, this time to develop small-molecule protein kinase B (PKB) to further contribute in the fight against cancer. AstraZeneca’s first acquisition following its creation was of KuDOS Pharmaceuticals, a UK biotech company, for £120 million in 2005.
Drug Discovery World
SEPTEMBER 5, 2022
Genome interpretation: To decipher genetic variants in cancer . The success of targeted therapies in cancer comes on the heels of identifying specific molecular targets resulting from genetic variations. When selecting patients for therapy, we currently look at variants that directly affect protein expression or function.
Expert insights. Personalized for you.
40 
Let's personalize your content